Imagene AI

Description

Imagene AI is at the forefront of precision medicine, utilizing multimodal foundation models to advance translational research and clinical development. Its Oncology Intelligence Engine continuously learns from imaging, molecular, and clinical data, empowering biopharma and clinical teams with advanced capabilities for biomarker discovery, patient stratification, response prediction, and companion diagnostic development. Imagene AI's pathology assays translate biological insights into patient-selection and diagnostic strategies, offering a comprehensive approach to precision oncology.

One of its notable offerings is the Lung Prediction Panel, an AI-powered research-use assay built on the CanvOI foundation model. This panel predicts the presence of eight genomic alteration biomarkers in non-small cell lung cancer (NSCLC) from H&E whole-slide images, providing results in minutes. The panel includes mutations such as EGFR, KRAS G12C, ERBB2, and BRAF V600E, as well as fusions like ALK, RET, and ROS1, and MET exon 14 skipping. These results can support sample prioritization across various research applications, including retrospective studies and biomarker analysis.

Imagene AI is driven by a multidisciplinary team of scientists, AI experts, physicians, and technology professionals committed to a patient-first mindset. The leadership team includes Dean Bitan as CEO and Co-founder, Jonathan Zalach as CDSO and Co-founder, and Shahar Porat as CTO and Co-founder. The company is supported by a Medical Advisory Board of world-leading experts in healthcare and precision oncology, including David Agus, MD, and Natasha Leighl, MD.

Imagene AI's mission is to democratize precision medicine, making every trial more responsive, every insight more actionable, and every patient journey more personalized. Its innovative approach unlocks powerful insights that drive new discoveries, turning cancer data into intelligence that can help today's patients and accelerate tomorrow's therapies.

Imagene AI's Core Features

• Multimodal foundation models

• Oncology Intelligence Engine

• Biomarker discovery

• Patient stratification

• Response prediction

• Companion diagnostic development

• AI-powered image analysis

• Lung Prediction Panel

How to use Imagene AI?

1. 1

   Configure: Set up the Oncology Intelligence Engine

2. 2

   Use: Analyze imaging, molecular, and clinical data

3. 3

   Optimize: Enhance biomarker discovery and patient stratification

4. 4

   Apply: Utilize pathology assays for diagnostic strategies

Imagene AI's Use Cases

• Biomarker discovery
• Patient stratification
• Response prediction
• Companion diagnostics
• Tissue stewardship

FAQ from Imagene AI

• What is Imagene AI's Oncology Intelligence Engine?

  It is a system that learns from imaging, molecular, and clinical data to empower biopharma and clinical teams with advanced capabilities.

• What is the Lung Prediction Panel?

  An AI-powered assay predicting genomic alteration biomarkers in NSCLC from H&E whole-slide images.

• Who are the key leaders at Imagene AI?

  Dean Bitan (CEO), Jonathan Zalach (CDSO), and Shahar Porat (CTO) are among the key leaders.

• What types of mutations does the Lung Prediction Panel detect?

  It detects mutations such as EGFR, KRAS G12C, ERBB2, and BRAF V600E, among others.

• How does Imagene AI support precision medicine?

  By using multimodal foundation models to enhance translational research and clinical development.

• What is the mission of Imagene AI?

  To democratize precision medicine and make trials more responsive and insights more actionable.

• Who are the experts on Imagene AI's Medical Advisory Board?

  Experts include David Agus, MD, Natasha Leighl, MD, and Christian Rolfo, MD, PhD.

• What is the CanvOI foundation model?

  It is the foundation model on which the Lung Prediction Panel is built.